CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 14 enrolled
Drug / intervention
Dronabinoldrug
Likely dose
Dronabinol 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04374773
NCT04374773Phase 4Completed

Effect of Estradiol and Cortisol on Marinol Metabolism

University of Washington·interventional·Posted May 5, 2020·Updated May 6, 2026

In Brief

A Phase 4 clinical trial evaluating Dronabinol for Pregnancy Related and Cannabis Use. Completed, enrolled 14 participants across 1 site.

Detailed Summary

Cannabis use is prevalent among pregnant women, but the effects of use on both the developing fetus and pregnant woman are unknown. Importantly, drug exposure could be influenced by the impact of pregnancy-associated hormones on the metabolism of tetrahydrocannabinol (THC), the main psychoactive component of cannabis. The goal of this study is to determine whether cortisol and estradiol - hormones that rise dramatically during pregnancy - increase the clearance of dronabinol (THC) in reproductive age women to simulate the pregnant state. The collected data will then be used to predict the time course and magnitude of changes in THC metabolism in pregnant women, particularly with gradually increasing estradiol and cortisol concentrations that evolve over the course of pregnancy. The overall objective of this study is to better understand the effects of THC use during pregnancy on the health of the pregnant woman and developing fetus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 5, 2020
Enrollment StartOct 19, 2020
Primary CompletionFeb 14, 2026
Study CompletionFeb 28, 2026
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 6.2 years ago

Interventions

Dronabinoldrug

2.5 mg PO administered once prior to and once after 1 week of hormone therapy